상세 보기
Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
- Kim, Tae Min;
- Lakhani, Nehal J.;
- Soumerai, Jacob;
- Kamdar, Manali;
- Gainor, Justin F.;
- ... Kim, Won Seog;
- 외 8명
WEB OF SCIENCE
19SCOPUS
16초록
CD47 overexpression has been associated with tumor cell survival. We present the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of evorpacept, a novel fusion protein comprising a high-affinity CD47-SIRP alpha immune checkpoint inhibitor to promote tumor cell phagocytosis and inactive Fc domain to spare healthy cells, plus rituximab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) from the phase I ASPEN-01 study. Thirty-three patients received intravenous evorpacept (10 mg/kg [N=22] or 15 mg/kg [N=11] once weekly) until disease progression, in combination with fixed-duration intravenous rituximab (375 mg/m2 once weekly for 4 weeks, then every 4 weeks for 8 months). Evorpacept plus rituximab was well tolerated, with no dose-limiting toxicities; no maximum tolerated dose was identified. The most common treatment-related adverse events (TRAE) were rash (24.2%) and fatigue (15.2%); most TRAE (70.0%) were mild-to-moderate in severity. Four (12.1%) patients reported grade 3 TRAE: anemia, neutropenia, decreased neutrophil count, increased alanine aminotransferase, decreased lymphocyte count, and decreased platelet count (1 of each). Two (6.1%) patients experienced grade 4 TRAE (neutropenia, decreased neutrophil count). Six (18.2%) patients experienced serious AE (not treatment-related): asthma, dyspnea, respiratory failure, gastrointestinal infection, pneumonia, cardiac failure, and disease progression (1 of each). Two (6.1%) deaths occurred (not treatment-related). Pharmacokinetics/ pharmacodynamics were consistent with previous studies, with complete CD47 target occupancy (>= 85%) achieved at both doses. In response-evaluable patients (N=32), objective response rate was 50.0% (95% confidence interval: 33.1-69.8%). The safety, tolerability, and promising anti-tumor activity of evorpacept plus rituximab support continued evaluation of this combination in NHL (clinicaltrials gov. Identifier: NCT03013218).
키워드
- 제목
- Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
- 저자
- Kim, Tae Min; Lakhani, Nehal J.; Soumerai, Jacob; Kamdar, Manali; Gainor, Justin F.; Messersmith, Wells; Fanning, Philip; Guan, Shanhong; Jin, Feng; Forgie, Alison; Wan, Hong I.; Pons, Jaume; Randolph, Sophia S.; Kim, Won Seog
- 발행일
- 2025-09
- 유형
- Article
- 저널명
- Haematologica
- 권
- 110
- 호
- 9
- 페이지
- 2102 ~ 2112
- 언어
- ENG
- 출판사
- FERRATA STORTI FOUNDATION
- 발행국가
- 이탈리아
- 분량
- 11 페이지
- ISSN
- E 1592-8721
P 0390-6078